Andere Sprachen Iovance Biotherapeutics, Inc.

Aktien

A2DT49

US4622601007

IOVA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
11,64 ^USD	+0,87 %		+2,92 %	+43,17 %

29.03.	General a.D. Merrill A. McPeak, Mitglied des Verwaltungsrats von Iovance Biotherapeutics, Inc. geht in den Ruhestand und stellt sich nicht zur Wiederwahl	CI
14.03.	IOVANCE BIOTHERAPEUTICS, INC. : Bewertung von Piper Sandler zum Kaufen erhalten	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting	24.04.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - April 19, 2024	22.04.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	19.04.
General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	29.03.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	25.03.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	22.03.
Iovance Biotherapeutics to Present at Upcoming Conferences	04.03.
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	04.03.
Iovance Biotherapeutics Says FDA Lifts Partial Clinical Hold on Lung Cancer Study	04.03.
Iovance Biotherapeutics Syas FDA Lifts Partial Clinical Hold on LN-145	04.03.
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer	04.03.
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer	04.03.
Iovance Biotherapeutics to Present at Upcoming Conferences	01.03.
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	29.02.
Iovance Biotherapeutics Q4 Loss Narrows, Posts Revenue	29.02.
Iovance Biotherapeutics: Q4 Earnings Snapshot	28.02.
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Reports Q4 Revenue $482,000	28.02.
Iovance Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	28.02.
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024	22.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Iovance Biotherapeutics, Inc.

Aktien

A2DT49

US4622601007

IOVA

Andere Sprachen

Filter